Dimed Distribuidora de Medicamentos Full Year 2023 Earnings: Revenues In Line With Expectations

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Full Year 2023 Results

Key Financial Results

• Revenue: R$4.46b (up 12% from FY 2022).
• Net income: R$92.9m (up 7.6% from FY 2022).
• Profit margin: 2.1% (in line with FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dimed Distribuidora de Medicamentos Meets Expectations

Revenue was in line with analyst estimates.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in Brazil.

Performance of the Brazilian Consumer Retailing industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Dimed Distribuidora de Medicamentos' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.